摘要
B族链球菌(GBS)是危害母婴健康的重要病原菌,也是导致新生儿死亡的重要因素之一。基于微生物筛查和(或)临床危险因素评估的产时抗生素治疗可有效降低GBS感染风险,是目前普遍采用的预防早发型GBS病的主要措施。随着抗菌药物耐药性的产生和传播,GBS疫苗的研发备受关注。荚膜多糖疫苗、荚膜多糖联合疫苗、蛋白疫苗已进入临床试验阶段,为B族链球菌围产期干预提供了新的手段。
Group B streptococcus(GBS)is an important pathogen that endangers maternal and infant health and is also the leading cause of neonatal death.Intrapartum antibiotic chemoprophylaxis based on microbiological screening and/or clinical risk factors can effectively reduce GBS infection and is currently the main measure to prevent early-onset GBS disease.With the emergence and spread of antibiotic resistance,the development of GBS vaccines has received increasing attention.Capsular polysaccharide vaccine,capsular polysaccharide conjugate vaccine and protein vaccine have been evaluated in the clinical trials,providing a new means for perinatal intervention of GBS.
作者
龚心怡
刘泽梁
李娟
GONG Xinyi;LIU Zeliang;LI Juan(National Institute for Communicable Disease Control and Prevention,Chinese Center for Disease Control and Prevention,State Key Laboratory for Communicable Diseases Prevention and Control,Beijing 102206,China)
出处
《中国病原生物学杂志》
CSCD
北大核心
2023年第6期729-733,共5页
Journal of Pathogen Biology
基金
“十三五”国家科技重大专项“病原菌耐药性检测、监测关键技术及传播规律研究”基金项目(No.2018XZ10733)。
关键词
B族链球菌
围产期
产前抗生素治疗
疫苗
综述
Group B streptococcus
perinatal period
intrapartum antibiotic chemoprophylaxis
vaccine
review